Get the Stockscreener App
58.78
0.56%
0.33
Arcellx Inc stock is traded at $58.78, with a volume of 609.41K.
It is up +0.56% in the last 24 hours and down -3.15% over the past month.
Arcellx Inc a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases. Its pipeline includes Multiple Myeloma, Acute Myeloid Leukemia, Non-Oncology, and Solid Tumors.
See More
Previous Close:
$58.45
Open:
$58.37
24h Volume:
609.41K
Relative Volume:
0.85
Market Cap:
$3.24B
Revenue:
$155.82M
Net Income/Loss:
$-40.42M
P/E Ratio:
-82.79
EPS:
-0.71
Net Cash Flow:
$3.58M
1W Performance:
+2.14%
1M Performance:
-3.15%
6M Performance:
-33.08%
1Y Performance:
+11.35%
1-Day Range:
$56.61
$59.13
1-Week Range:
$53.07
$65.91
52-Week Range:
$47.86
$107.37
Arcellx Inc Stock (ACLX) Company Profile
Name
Arcellx Inc
Sector
Industry
Phone
240-327-0603
Address
800 BRIDGE PARKWAY, REDWOOD CITY
Compare ACLX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ACLX
Arcellx Inc
|
58.78 | 3.17B | 155.82M | -40.42M | 3.58M | -0.71 |
|
ONC
Beigene Ltd Adr
|
228.38 | 25.07B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.65 | 109.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.27 | 36.39M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
594.32 | 56.98B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
71.31 | 5.39B | 0 | -153.72M | -103.81M | -2.00 |
Arcellx Inc Stock (ACLX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-08-24 | Initiated | Redburn Atlantic | Buy |
| Sep-03-24 | Initiated | Cantor Fitzgerald | Overweight |
| May-31-24 | Initiated | Piper Sandler | Overweight |
| Mar-07-24 | Initiated | Morgan Stanley | Overweight |
| Jan-04-24 | Reiterated | Needham | Buy |
| Dec-19-23 | Initiated | Scotiabank | Sector Outperform |
| Oct-30-23 | Initiated | TD Cowen | Outperform |
| Oct-17-23 | Initiated | UBS | Buy |
| May-18-23 | Initiated | Truist | Buy |
| Apr-14-23 | Initiated | Robert W. Baird | Outperform |
| Mar-14-23 | Initiated | Stifel | Buy |
| Feb-13-23 | Initiated | H.C. Wainwright | Buy |
| Dec-13-22 | Resumed | BofA Securities | Buy |
| Oct-31-22 | Initiated | Guggenheim | Buy |
| Oct-27-22 | Initiated | Needham | Buy |
| Jul-20-22 | Initiated | Canaccord Genuity | Buy |
| Mar-01-22 | Initiated | BofA Securities | Buy |
| Mar-01-22 | Initiated | SVB Leerink | Outperform |
View All
Arcellx Inc Stock (ACLX) Latest News
Arcellx, Inc. Reports Q1 2025 Financial Results - TipRanks
Arcellx Inc’s Anito-cel Shows Promising Results in Phase 2 Trial, Earning Buy Rating from Analyst - TipRanks
Insiders At Arcellx Sold US$2.6m In Stock, Alluding To Potential Weakness - simplywall.st
Promising Clinical Data and Strong Safety Profile Lead to Buy Rating for Arcellx Inc’s Anito-cel - TipRanks
Arcellx Inc’s Anito-cel Shows Promising Efficacy and Safety in Multiple Myeloma, Earning Buy Rating - TipRanks
Arcellx's Potential Multiple Myeloma Treatment Shows 97% Overall Response Rate in Phase 2 Study; Shares Rise - marketscreener.com
Promising Clinical Trial Results and Safety Profile Support Buy Rating for Arcellx Inc’s Anito-cel Therapy - TipRanks
Arcellx Announces Positive Phase 2 Study Results - TipRanks
Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients with Relapsed and/or Refractory Multiple Myeloma - BioSpace
Arcellx Reports Positive Data From Phase 2 IMMagine-1 Study - Nasdaq
Arcellx announces data from iMMagine-1 study of anitocabtagene autoleucel - TipRanks
Arcellx, Inc. Announces New Positive Data for Its Immagine-1 Study in Patients with Relapsed And/Or Refractory Multiple Myeloma - marketscreener.com
Arcellx Inc.: Strong Financial Position and Promising Phase 2 Study Outcomes Drive Buy Rating - TipRanks
Blood Cancer Treatment Market Sees Accelerated Growth Across the 7MM Amid Rising Incidence and Breakthroughs | DelveInsight - GlobeNewswire Inc.
Here’s Why Arcellx (ACLX) Declined in Q1 - Insider Monkey
Piper Sandler Remains a Buy on Arcellx Inc (ACLX) - The Globe and Mail
Arcellx Inc (ACLX) Receives a Buy from Scotiabank - The Globe and Mail
Arcellx First Quarter 2025 Earnings: Misses Expectations - Yahoo Finance
Arcellx (ACLX) Maintains Rating as Price Target is Lowered by Sc - GuruFocus
Arcellx price target lowered to $93 from $133 at Scotiabank - TipRanks
Arcellx, Inc. (ACLX) Reports Q1 Loss, Lags Revenue Estimates - MSN
Promising Potential of Arcellx Inc’s Anito-cel Therapy: A Buy Rating Backed by Positive Study Data and Strategic Trial Enhancements - TipRanks
Arcellx (ACLX): Scotiabank Adjusts Price Target Amid Regulatory Concerns | ACLX Stock News - GuruFocus
Arcellx’s Promising Trial Results and Strategic Partnerships Justify Buy Rating with $121 Target - TipRanks
Arcellx Inc. Receives Buy Rating: Strong Financial Outlook and Promising Data Catalysts - TipRanks
Promising Potential of Arcellx Inc’s Anito-cel Program Drives Buy Rating - TipRanks
ARCELLX Earnings Results: $ACLX Reports Quarterly Earnings - Nasdaq
Earnings Flash (ACLX) ARCELLX INC. Reports Q1 Revenue $8.1M, vs. FactSet Est of $19.5M - marketscreener.com
Arcellx Provides First Quarter 2025 Financial Results and Business Highlights - Business Wire
Before Buying Arcellx Inc (NASDAQ: ACLX) Stock, Read This First - Stocksregister
Arcellx, Inc. (NASDAQ:ACLX) Stake Reduced by Envestnet Asset Management Inc. - Defense World
Investor’s Toolkit: Key Ratios for Assessing Arcellx Inc (ACLX)’s Performance - DWinneX
Dimensional Fund Advisors LP Buys 186,013 Shares of Arcellx, Inc. (NASDAQ:ACLX) - Defense World
Arcellx (ACLX) to Release Quarterly Earnings on Thursday - Defense World
Arcellx Enters Oversold Territory (ACLX) - Nasdaq
Arcellx, Inc. (NASDAQ:ACLX) Shares Acquired by Invesco Ltd. - Defense World
(ACLX) Technical Pivots with Risk Controls - news.stocktradersdaily.com
Wells Fargo & Company MN Has $2.04 Million Holdings in Arcellx, Inc. (NASDAQ:ACLX) - Defense World
William Blair Sticks to Its Buy Rating for Arcellx Inc (ACLX) - The Globe and Mail
Arcellx, Inc. (ACLX): Among Takeover Rumors Hedge Funds Are Buying - EMEA Tribune
Alliancebernstein L.P. Sells 6,181 Shares of Arcellx, Inc. (NASDAQ:ACLX) - Defense World
(ACLX) Proactive Strategies - news.stocktradersdaily.com
Wellington Management Group LLP Trims Holdings in Arcellx, Inc. (NASDAQ:ACLX) - Defense World
Insider Selling: Arcellx, Inc. (NASDAQ:ACLX) Director Sells 1,500 Shares of Stock - MarketBeat
Arcellx (ACLX): Among Billionaire Stanley Druckenmiller’s Top Stock Picks with Huge Upside Potential - Insider Monkey
Arcellx (NASDAQ:ACLX) Trading Down 6.8% on Insider Selling - Defense World
Gilead's Kite, Arcellx share phase 3 trial design for CAR-T multiple myeloma asset - MSN
Arcellx director Kavita Patel sells shares worth $86,250 By Investing.com - Investing.com Australia
Sei Investments Co. Purchases 4,827 Shares of Arcellx, Inc. (NASDAQ:ACLX) - Defense World
Arcellx director Kavita Patel sells shares worth $86,250 - Investing.com
29,446 Shares in Arcellx, Inc. (NASDAQ:ACLX) Purchased by American Century Companies Inc. - Defense World
Arcellx Inc Stock (ACLX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.54%
7.58%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):